Drugmakers agree to halve prices to secure access to China

Astrazeneca, Glaxosmithkline and Novo Nordisk amongst companies to cut drug prices in China.

Photo: Novo Nordisk / PR

Drugmakers from Astrazeneca and GlaxoSmithKline to BeiGene Ltd. agreed to cut prices on some of their newest drugs in China by an average of 51% in order to be covered by the country’s national insurance fund.

A total of 119 new therapies -- treating ailments from pulmonary diseases and diabetes to cancers and lupus -- were added for coverage by the state-run medical safety net after drawn-out negotiations, the National Healthcare Security Administration said in a notice posted on its website Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs